ClinicalTrials.gg
Sign In
RecruitingNCT07390890Updated Apr 20, 2026

DSLT for Reducing Medication in Glaucoma

An observational study in Primary Open Angle Glaucoma and Ocular Hypertension, sponsored by The Eye Institute of West Florida. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by The Eye Institute of West Florida · Observational

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Sex
All
01

Study summary

This is a prospective, single arm, open label study conducted at a single site to evaluate the efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in reducing medication burden in patients with medically controlled ocular hypertension or primary open angle glaucoma.

The study will assess the primary endpoint of reduction in medication count at 6 months compared to baseline. Secondary endpoints include IOP reduction compared to baseline (both percentage and absolute), complete success rate (no increase in IOP without medications), proportion of eyes needing medication at 6 months, and any secondary surgical interventions at 6 months post-DSLT.

Participants will undergo DSLT with 120 shots, 400 µm spot size, and 1.8mJ fixed energy delivered at the limbus over 2.4 seconds. Follow-up visits will occur at 1 month, 3 months, and 6 months post-procedure, with IOP measured using a calibrated Goldmann tonometer.

02

Conditions studied

  • Primary Open Angle Glaucoma
  • Ocular Hypertension
03

In context

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 117 are open to participants now.

This study's planned enrollment of 60 is below the median of 101 across 184 observational studies indexed under Glaucoma, Open-Angle.

Browse Glaucoma, Open-Angle studies →

Lead sponsor

The Eye Institute of West Florida is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with ocular hypertension or POAG undergoing DSLT treatment in one or both eyes.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients scheduled to undergo DSLT treatment in one or both eyes.

    • Diagnosis of ocular hypertension or primary open angle glaucoma (POAG).
  • Medically controlled on 1-3 topical ocular hypotensive agents with IOP ≤21 mmHg.

Exclusion criteria

Exclusion Criteria:

  • Previous glaucoma surgeries/interventions:

    • Patients who have undergone prior glaucoma-related procedures (e.g., trabeculectomy, laser trabeculoplasty, MIGS, or tube shunt).
  • Patients who have undergone cataract surgery within the prior 2 years.

  • Secondary glaucoma:

    • Patients with secondary forms of glaucoma, such as angle-closure glaucoma, neovascular glaucoma, or glaucoma resulting from trauma or other systemic diseases.
  • Other significant ocular conditions including advanced cataracts, retinal diseases (e.g., age-related macular degeneration), or any condition that might complicate the assessment of intraocular pressure (IOP) or visual function as deemed by the investigator.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)

Interventions

  • DeviceVoyager DSLT

    Voyager DSLT

06

What researchers measure

Primary outcomes

  1. Reduction in the number of glaucoma medications required to maintain target intraocular pressure (IOP)

    The primary outcome will be assessed by comparing the number of medications needed to maintain target IOP before and after DSLT treatment.

    Time frame: 6 months post-DSLT treatment

Secondary outcomes

  1. Change in intraocular pressure (IOP) from baseline

    IOP will be measured using Goldmann applanation tonometry at each follow-up visit.

    Time frame: 6 months post-DSLT treatment

  2. Proportion of eyes needing medication stratified by number of IOP medications required

    Time frame: 6 months post-DSLT treatment

  3. Number and type of Secondary surgical interventions

    Time frame: 6 months post-DSLT treatment

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jan 2027, 11 months after the start.

Of 53 observational studies under Glaucoma, Open-Angle, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2026
First posted
Feb 5, 2026
StartActual
Feb 10, 2026
Primary completionEst.
Jan 26, 2027
CompletionEst.
Jan 26, 2027
Last update
Apr 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07390890
Lead sponsor
The Eye Institute of West Florida
Collaborators
Sengi
Responsible party
Sponsor
First posted
Feb 5, 2026
Start date
Feb 10, 2026
Primary completion
Jan 26, 2027 (estimated)
Completion
Jan 26, 2027 (estimated)
Last update
Apr 20, 2026

Study contacts

Renee Bondurant
Contact
Renee.Bondurant@eyespecialist.com
727-450-4668
Neel Desai, MD
principal investigator · The Eye Institute of West Florida

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Glaucoma, Open-Angle →

Other studies from this sponsor

The Eye Institute of West Florida

Start the discussion